2. Contents
1. Receptor and its types
2. Physiology of GPCR
3. GPCR as target for drug designing
4. GPCR associated diseases
5. Future prospects and conclusions
3. Definition
• A receptor is defined as a macromolecule or binding site
located on the surface or inside of the effector cell that
serves to recognize the signal molecule/drug and initiate the
response to it, but itself has no other function.
4. Types of receptors
1. G- protein receptors : largest
2. Ion channel receptors/ ligand gated receptors : fastest
3. Transmembrane enzyme-linked receptors : eg tyrosine
kinase
4. Jak-stat receptors : JAK- Janus kinase, STAT – signal
transducer and activator of transcription. Eg. Cytokines,
GH, prolactin, interferons
5. Nuclear receptors : steroids, thyroxine, vit D, vit A.
8. Actions of G-alpha
• Gs Adenylyl cyclase activation
Ca channel opening
• Gi Adenynyl cyclase inhibition
K+ channel opening
• Go Ca channel inhibition
• Gq Phospholipase C activation
9. 3 Major Pathways of GPCR
1.CAMP Dependant Pathway
2. Phospholipase C : IP3- DAG pathway
3. Channel regulation
10. cAMP dependant effects
1. Via protein kinase A
• Increased contractility of heart
• Relaxation of smooth muscles
• Glycogenolysis, lipolysis
• Water conservation by kidneys
• Steroid hormone synthesis
2. cAMP response element binding protein(CREB)
3. EPACs (CAMP regulated guanine nucleotide exchange factors)
13. GPCR as drug targets
Receptor Drug and some key indication
Alpha-1 receptor Antagonist eg Tamsulosin to treat
enlarged prostate
Beta-1 Antagonists eg propranolol, atenolol for
hypertension
Beta-2 Agonists in bronchial asthma
D-2 Antagonists eg haloperidol , clozapine in
schizophrenia
Agonists eg levodopa in parkinsons
14.
15. Diseases associated with G-proteins
1. Gene mutations: loss of function eg color blindness
gain of function
2. Bacterial toxins: Eg cholera
3. Altered GPCR folding
16. Orphan GPCR
• Receptors which lack their pharmacological identity
• Focus of intense research
• First orphan GPCR was G21 later found to be 5HT1A
17. Recent developments
• Ligand- induced selective signalling (LISS): It states that
different ligand selectively recruits different intracellular
signalling protein to produce different phenotypic effects.
• There are many ways GPCR can signal independently of G-
proteins. A case has been made to abandon the term as couple
receptor and call them transmembrane receptors.
• GPCR are new therapeutic targets for type 2 diabetes.